Literature DB >> 32769297

5-Fluorouracil induced extravasation injury.

Sangana Sunitha Reddy1, Shalaka Somayaji1, Mamatha Krishna Murthy1, Vinayak V Maka2.   

Abstract

Antineoplastic drugs based on their ability to cause local damage are classified as irritants, vesicants, and non-vesicants. Previous literature has reported higher rate of vesicants induced extravasation (EV) compared to irritants. We report the first case of irritant, 5-fluorouracil causing grade III EV in 55-year-old woman. The patient was diagnosed with esophageal squamous cell carcinoma. Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) chemotherapy regimen was planned and administered through peripheral venous access. Patient experienced grade 3 extravasation in her 3rd cycle following 5-fluorouracil (5-FU) administration. The suspected drug was withdrawn immediately and discontinued from the 4th cycle of the regimen. The patient completely recovered from the symptoms of pain and erythema in the next cycle and care was taken not to infuse drug in the same site again. Since there is no appropriate antidote available to manage this condition, measures need to be taken to identify the predisposing factors for EV and prevent them.

Entities:  

Keywords:  5-fluorouracil; carcinoma; chemotherapy; extravasation

Mesh:

Substances:

Year:  2020        PMID: 32769297     DOI: 10.4103/ijc.IJC_281_19

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  2 in total

1.  Regimen of 5-Fluorouracil and Cisplatin Increases the Incidence of Extravasation in Patients Undergoing Chemotherapy.

Authors:  Hisashi Tagashira; Yasuhisa Izushi; Tomoki Ikuta; Yasumasa Koike; Yoshihisa Kitamura; Hiroshi Yamamoto
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

2.  Efficacy of combination of localized closure, ethacridine lactate dressing, and phototherapy in treatment of severe extravasation injuries: A case series.

Authors:  Yan-Xu Lu; Ying Wu; Peng-Fei Liang; Rong-Chan Wu; Ling-Yun Tian; Hui-Ying Mo
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.